Treatment of chronic hepatitis B: Are we ready for combination therapy?

Current Gastroenterology Reports

Volumn 11, Issue 1, 2009, Pages 22-27

  Seetharam, Anil ^b   Lisker Melman, Mauricio ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; CLEVUDINE; EMTRICITABINE; ENTECAVIR; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 12; LAMIVUDINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; THYMOSIN ALPHA1; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MONOTHERAPY; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS;

EID: 58849156898     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0004-8     Document Type: Review

References (32)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11: 97-107.
2. Centers for Disease Control and Prevention: Viral hepatitis. Available at www.cdc.gov/ncidod/diseases/hepatitis/resource/dz_burden02.htm. Accessed October 2008.
3. Liaw YF, Sung JJ, Chow WC, et al.: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351: 1521-1531.
4. Locarnini S, Birch C: Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIVinfected patients. J Hepatol 1999, 30: 536-550.
5. Yim HJ, Hussain M, Liu Y, et al.: Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006, 44: 703-712.
6. Brunelle MN, Jacquard AC, Pichoud C, et al.: Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41: 1391-1398.
7. Bartholomeusz A, LocaCnini SA: Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006, 26: 162-170.
8. Ono-Nita SK, Kato N, Shiratori Y, et al.: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999, 29: 939-945.
9. Fung SK, Chae HB, Fontana RJ, et al.: Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006, 44: 283-290.
10. Han S, Chang TT, Chao YC, et al.: Four-year entecavir treatment in nucleosidenaive HbeAg+ patients: Results from studies ETV-022 and -901 [abstract 938]. Hepatology 2007, 46(Suppl 1): 654A.
11. Marcellin P, Buti M, Krastev Z, et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102 [abstract LB2]. Hepatology 2007, 46(Suppl 1): 290A-291A.
12. Heathcote EJ, Gane E, DeMan R, et al.: A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103 [abstract LB6]. Hepatology 2007, 46(Suppl 1): 861A.
13. Gish R, Chang TT, Lai CL, et al.: Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg(+) chronic hepatitis B infection: observations from antiviralnaive patients treated with entecavir (ETV) or lamivudine (LVD) [abstract 992]. Hepatology 2006, 44(suppl 1): 558A.
14. Gish RG, Lok AS, Chang TT, et al.: Entecavir therapy for up to 96 weeks in patients with HbeAg-positive chronic hepatitis B. Gastroenterology 2007, 133: 1437-1444.
15. Lampertico P, Vigano M, Manenti E, et al.: Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133: 1445-1451.
16. AIDS information available at http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf.
17. Naoumov NV, Rossol S: Studies of interleukin-12 in chronic hepatitis B virus infection. J Viral Hepat 1997, 4(Suppl 2): 87-91.
18. Lim SG, Wai CT, Lee YM, et al.: A randomized, placebocontrolled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006, 11: 245-253.
19. Peters MG, Hann H, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126: 91-101.
20. Yeon JE, Yoo W, Hong SP, et al.: Resistance to adefovir dipivoxil (ADV) in lamivudine resistant chronic hepatitis B patients with treated with ADV. Gut 2006, 55: 1488-1495.
21. Lee YS, Suh DJ, Lim YS, et al.: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43: 1385-1391.
22. Marcellin P, Lau GK, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351: 1206-1217.
23. Zoulim F: Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004, 64: 1-15.
24. Schalm SW, Heathcote J, Cianciara J, et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000, 46: 562-568.
25. Barbaro G, Zechini F, Pellicelli AM, et al.: Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001, 35: 406-411.
26. Yalcin K, Degertekin H, Yildiz F, Celik Y: Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003, 36: 1516-1522.
27. Deng H, Zhao ZX, Xu QH, et al.: Therapy effect of lamivudine combination with alpha interferon on patients with chronic hepatitis B [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003, 11: 305-308.
28. Marcellin P, Piratvisuth T, Brunetto M, et al.: Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peg-interferon alfa-2a (40KD) with or without lamivudine: results of 4 year follow-up [abstract 103]. J Hepatol 2008, 48(Suppl 2): S46.
29. Sugahara S, Ichida T, Yamagiwa S, et al.: Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res 2002, 24: 346-354.
30. Cavanaugh VJ, Guidotti LG, Chisari FV: Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997, 71: 3236-3243.
31. Lohr HF, Pingel S, Bocher WO, et al.: Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B: Restoration by exogenous interleukin-12. Clin Exp Immunol 2002, 130: 107-114.
32. Rigopoulou EI, Suri D, Chokshi S, et al.: Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity. Hepatology 2005, 42: 1028-1036.